...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer and Clinical Oncology >Four Week Hypofractionated Accelerated Intensity Modulated Radiotherapy and Synchronous Carboplatin or Cetuximab in Biologically Staged Oropharyngeal Carcinoma
【24h】

Four Week Hypofractionated Accelerated Intensity Modulated Radiotherapy and Synchronous Carboplatin or Cetuximab in Biologically Staged Oropharyngeal Carcinoma

机译：在生物学上分期的口咽癌中进行为期四周的超分割加速调强放射治疗和同步卡铂或西妥昔单抗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hypofractionated accelerated chemoradiotherapy in the conformal era achieved acceptable control rates for squamous cell carcinoma of the head and neck. This study reports outcomes for biologically staged oropharyngeal cancer treated using four-week intensity-modulated radiotherapy (IMRT) and synchronous chemotherapy. Between 2009–2012, patients with squamous cell carcinoma of the oropharynx treated with hypofractionated chemo-IMRT (55Gray in 20 fractions), with either carboplatin or cetuximab were prospectively identified. Outcome measures analysed were 2-year loco-regional recurrence-free survival (LR-RFS) and overall survival (OS). Eighty-five consecutive patients with oropharyngeal cancer (p16 positive never smoked n=17; p16 positive ever smoked n=42; p16 negative n=24; unknown n=2)) were treated with IMRT with carboplatin (n=69) or cetuximab (n=16), with median follow up in surviving patients of 26 months. Two year LR-RFS was 68% for the whole cohort (95% confidence intervals 58%-78%), 87% (58%–97%) for the p16 positive never-smokers, 75% (58%–86%) for the p16 positive ever-smokers and 45% (25%–63%) for the p16 negative patients. OS at 24 months for these groups respectively was 80% (69–87%), 100.0%, 90% (75%–96%) and 46.9% (25%–66%). Factors associated with a worse OS on multivariate analysis were p16 negativity (p60 (p=0.048), increasing T stage (p=0.021) and contraindication to carboplatin (p<0.001). The acceptable efficacy obtained with this schedule questions the need for synchronous cisplatin in good prognosis groups of oropharyngeal carcinoma. These results may also prompt the examination of a 4 week schedule of chemoradiotherapy in future randomised trials.
机译：保形时代的超分割加速放化疗已获得可接受的头颈部鳞状细胞癌控制率。这项研究报告了使用为期四周的调强放疗（IMRT）和同步化疗治疗的生物学阶段性口咽癌的结果。在2009年至2012年之间，前瞻性鉴定了用低级化学IMRT（55灰分，共20份），卡铂或西妥昔单抗治疗的口咽鳞状细胞癌患者。分析的结果指标为2年局部无复发生存期（LR-RFS）和总体生存期（OS）。连续八十五例口咽癌患者（p16阳性不吸烟n = 17; p16阳性不吸烟n = 42; p16阴性n = 24;未知n = 2））接受IMRT联合卡铂（n = 69）或西妥昔单抗治疗（n = 16），存活患者的中位随访时间为26个月。整个队列的两年LR-RFS为68％（95％置信区间58％-78％），p16阳性不吸烟者为87％（58％-97％），75％ p16阳性长期吸烟者为％（58 ％– 86 ％），p16阴性患者为45 ％（25 ％– 63 ％）。这些组在24个月时的OS分别为80％（69-87％），100.0％，90％（75％-96％）和46.9％（25％-66％）。在多因素分析中，与OS较差相关的因素是p16阴性（p60（p = 0.048），T期增加（p = 0.021）和卡铂禁忌症（p <0.001）。顺铂在口咽癌预后良好的人群中，这些结果也可能促使在以后的随机试验中检查放疗4周的时间表。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号